2023
Dexamethasone to prevent everolimus-induced stomatitis (Alliance MIST Trial: A221701)
Ruddy K, Zahrieh D, He J, Waechter B, Holleran J, Lewis L, Chow S, Beumer J, Weiss M, Trikalinos N, Faller B, Lustberg M, Rugo H, Loprinzi C. Dexamethasone to prevent everolimus-induced stomatitis (Alliance MIST Trial: A221701). Seminars In Oncology 2023, 50: 7-10. PMID: 36693773, PMCID: PMC10247389, DOI: 10.1053/j.seminoncol.2023.01.001.Peer-Reviewed Original ResearchConceptsMTOR inhibitor-associated stomatitisDexamethasone mouthwashCoprimary endpointsTrough concentrationsExact testRandomized phase III trialEverolimus trough concentrationsPrior clinical researchPhase III trialsDose-limiting toxicityFisher's exact testMann-Whitney U testWilcoxon rank sum testRank sum testOral everolimusIII trialsOral stomatitisTreatment periodMouth rinseMTOR inhibitorsPoor enrollmentClinical researchEverolimusU testStomatitis
2014
Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction
Berger M, Vargo C, Vincent M, Shaver K, Phillips G, Layman R, Macrae E, Mrozek E, Ramaswamy B, Wesolowski R, Shapiro C, Lustberg M. Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Supportive Care In Cancer 2014, 23: 2019-2024. PMID: 25519756, PMCID: PMC4804339, DOI: 10.1007/s00520-014-2556-x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Agents, PhytogenicAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsDexamethasoneDiphenhydramineDrug Administration ScheduleDrug HypersensitivityFamotidineFemaleHumansInfusions, IntravenousMiddle AgedNeoplasm StagingPaclitaxelPremedicationProspective StudiesRetrospective StudiesConceptsInfusion hypersensitivity reactionPaclitaxel-based chemotherapyRescue medication useBreast cancer patientsHypersensitivity reactionsPaclitaxel dosesRescue medicationMedication useSecond doseCancer patientsBreast cancerLife-threatening complicationsMajority of patientsDoses of paclitaxelProspective pilot trialUse of paclitaxelBreast cancer treatmentPrimary endpointInfusion reactionsPremedication regimenSubsequent dosesUnwanted side effectsResultsIn totalPilot trialStudy population
2013
Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy
Wenzell C, Berger M, Blazer M, Crawford B, Griffith N, Wesolowski R, Lustberg M, Phillips G, Ramaswamy B, Mrozek E, Flynn J, Shapiro C, Layman R. Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy. Supportive Care In Cancer 2013, 21: 2845-2851. PMID: 23748485, PMCID: PMC3769492, DOI: 10.1007/s00520-013-1865-9.Peer-Reviewed Original ResearchConceptsDay 1Emetogenic chemotherapyCR rateDay 2Doxorubicin/cyclophosphamide chemotherapyPilot studyOverall complete responseSame patient populationAntiemetic regimenAntiemetic regimensPAD armCyclophosphamide chemotherapyPrimary endpointFeared complicationComplete responseProspective studyPatient populationResultsA totalBreast cancerPatientsRegimensChemotherapyOverall CROndansetronDescriptive statistics
2011
Pneumocystis jiroveci Pneumonia in an Atypical Host
Reinbolt R, Alam S, Layman R, Shapiro C, Lustberg M. Pneumocystis jiroveci Pneumonia in an Atypical Host. Clinical Breast Cancer 2011, 12: 138-141. PMID: 22133356, PMCID: PMC3498486, DOI: 10.1016/j.clbc.2011.10.003.Peer-Reviewed Original ResearchAdrenal Cortex HormonesAntibodies, Monoclonal, HumanizedAnti-Infective AgentsAntineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideBevacizumabBreast NeoplasmsCD4 Lymphocyte CountClinical Trials, Phase I as TopicDexamethasoneErlotinib HydrochlorideFemaleHumansLung NeoplasmsMiddle AgedNeoplasm Recurrence, LocalNitrogen Mustard CompoundsPaclitaxelPneumocystis cariniiPneumonia, PneumocystisQuinazolinesTrimethoprim, Sulfamethoxazole Drug CombinationFeasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction
Berger M, Dunlea L, Rettig A, Lustberg M, Phillips G, Shapiro C. Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Supportive Care In Cancer 2011, 20: 1991-1997. PMID: 22089428, PMCID: PMC3411299, DOI: 10.1007/s00520-011-1303-9.Peer-Reviewed Original ResearchConceptsInfusion hypersensitivity reactionPaclitaxel-based chemotherapyHypersensitivity reactionsRescue medicationPaclitaxel dosesSecond doseDoses of paclitaxelBreast cancer patientsUse of paclitaxelPotential unwanted side effectsConclusionsIn patientsPrimary endpointSubsequent dosesUnwanted side effectsCancer patientsPremedicationSide effectsPatientsSolid tumorsDoses 3MedicationsChemotherapyDosesHypersensitivityDose